References
- Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II epidemiology report. Ocul Surf. 2017;15(3):334–365. doi:https://doi.org/10.1016/j.jtos.2017.05.003.
- Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol. 2000;118(9):1264–1268. doi:https://doi.org/10.1001/archopht.118.9.1264.
- Buchholz P, Steeds CS, Stern LS, et al. Utility assessment to measure the impact of dry eye disease. Ocul Surf. 2006;4(3):155–161.
- Karakus S, Mathews PM, Agrawal D, Henrich C, Ramulu PY, Akpek EK. Impact of dry eye on prolonged reading. Optom Vis Sci. 2018;95(12):1105–1113. doi:https://doi.org/10.1097/OPX.0000000000001303.
- Labbé A, Wang YX, Jie Y, Baudouin C, Jonas JB, Xu L. Dry eye disease, dry eye symptoms and depression: the Beijing eye study. British J Ophthalmol. 2013;97(11):1399–1403. doi:https://doi.org/10.1136/bjophthalmol-2013-303838.
- Le Q, Zhou X, Ge L, Wu L, Hong J, Xu J. Impact of dry eye syndrome on vision-related quality of life in a non-clinic-based general population. BMC Ophthalmol. 2012;12(1):1–8. doi:https://doi.org/10.1186/1471-2415-12-22.
- Yu J, Asche CV, Fairchild CJ. The economic burden of dry eye disease in the United States: a decision tree analysis. Cornea. 2011;30(4):379–387. doi:https://doi.org/10.1097/ICO.0b013e3181f7f363.
- Liu A Novartis/Takeda’s Xiidra. Published 2020; Accessed 12 September, 2020. https://www.fiercepharma.com/special-report/10-novartis-takeda-s-xiidra
- Insights FB. Artificial tears market to reach USD 4.30 billion by 2027; increasing knowledge about conjunctivitis and other eye disorders to foster growth, states fortune business insights. Fortune Business Insights. https://www.globenewswire.com/news-release/2020/08/24/2082704/0/en/Artificial-Tears-Market-to-Reach-USD-4-30-Billion-by-2027-Increasing-Knowledge-about-Conjunctivitis-and-Other-Eye-Disorders-to-Foster-Growth-states-Fortune-Business-Insights.html. Accessed September 12, 2020.
- Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3):276–283. doi:https://doi.org/10.1016/j.jtos.2017.05.008.
- Wolffsohn JS, Arita R, Chalmers R, et al. TFOS DEWS II diagnostic methodology report. Ocul Surf. 2017;15(3):539–574. doi:https://doi.org/10.1016/j.jtos.2017.05.001.
- Seitzman GD, Lietman TM. Dry eye research—Still regressing? Ophthalmology. 2019;126(2):192–194. doi:https://doi.org/10.1016/j.ophtha.2018.09.046.
- Guillemin I, Begley C, Chalmers R, Baudouin C, Arnould B. Appraisal of patient-reported outcome instruments available for randomized clinical trials in dry eye: revisiting the standards. Ocul Surf. 2012;10(2):84–99. doi:https://doi.org/10.1016/j.jtos.2012.01.007.
- Chalmers RL, Begley CG, Caffery B. Validation of the 5-Item Dry Eye Questionnaire (DEQ-5): discrimination across self-assessed severity and aqueous tear deficient dry eye diagnoses. Contact Lens Anterior Eye. 2010;33(2):55–60. doi:https://doi.org/10.1016/j.clae.2009.12.010.
- US Food and Drug Administration. Dry eye: developing drugs for treatment guidance for industry; 2020. https://www.fda.gov/media/144594/download.In. Retrieved October 5, 2021.
- Schaumberg DA, Gulati A, Mathers WD, et al. Development and validation of a short global dry eye symptom index. Ocul Surf. 2007;5(1):50–57. doi:https://doi.org/10.1016/S1542-0124(12)70053-8.
- Nilforoushan M-R, Latkany RA, Speaker MG. Effect of artificial tears on visual acuity. Am J Ophthalmol. 2005;140(5):830–835. doi:https://doi.org/10.1016/j.ajo.2005.05.001.
- Kaido M. Functional visual acuity. Invest Ophthalmol Vis Sci. 2018;59(14):DES29–DES35. doi:https://doi.org/10.1167/iovs.17-23721.
- Elhusseiny AM, Khalil AA, El Sheikh RH, Bakr MA, Eissa MG, El Sayed YM. New approaches for diagnosis of dry eye disease. Int J Ophthalmol. 2019;12(10):1618. doi:https://doi.org/10.18240/ijo.2019.10.15.
- Mengher LS, Bron AJ, Tonge SR, Gilbert DJ. Effect of fluorescein instillation on the pre-corneal tear film stability. Curr Eye Res. 1985;4(1):9–12. doi:https://doi.org/10.3109/02713688508999961.
- Smith J, Nichols KK, Baldwin EK. Current patterns in the use of diagnostic tests in dry eye evaluation. Cornea. 2008;27(6):656–662. doi:https://doi.org/10.1097/01.ico.0000611384.81547.8d.
- Sullivan BD, Crews LA, Sönmez B, et al. Clinical utility of objective tests for dry eye disease: variability over time and implications for clinical trials and disease management. Cornea. 2012;31(9):1000–1008. doi:https://doi.org/10.1097/ICO.0b013e318242fd60.
- Wang MT, Murphy PJ, Blades KJ, Craig JP. Comparison of non‐invasive tear film stability measurement techniques. Clin Exp Optometry. 2018;101(1):13–17. doi:https://doi.org/10.1111/cxo.12546.
- Kaido M, Matsumoto Y, Shigeno Y, Ishida R, Dogru M, Tsubota K. Corneal fluorescein staining correlates with visual function in dry eye patients. Invest Ophthalmol Vis Sci. 2011;52(13):9516–9522. doi:https://doi.org/10.1167/iovs.11-8412.
- Kaido M, Ishida R, Dogru M, Tamaoki T, Tsubota K. Efficacy of punctum plug treatment in short break-up time dry eye. Optometry Vision Sci. 2008;85:E758–E763.
- Kaido M, Ishida R, Dogru M, Tsubota K. The relation of functional visual acuity measurement methodology to tear functions and ocular surface status. Jpn J Ophthalmol. 2011;55(5):451–459. doi:https://doi.org/10.1007/s10384-011-0049-8.
- Sullivan BD, Whitmer D, Nichols KK, et al. An objective approach to dry eye disease severity. Invest Ophthalmol Vis Sci. 2010;51(12):6125–6130. doi:https://doi.org/10.1167/iovs.10-5390.
- Ridder WH III, Zhang Y, Huang J-F. Evaluation of reading speed and contrast sensitivity in dry eye disease. Optometry Vision Sci. 2013;90(1):37–44. doi:https://doi.org/10.1097/OPX.0b013e3182780dbb.
- Pult H, Purslow C, Murphy PJ. The relationship between clinical signs and dry eye symptoms. Eye. 2011;25(4):502–510. doi:https://doi.org/10.1038/eye.2010.228.
- Lemp MA. Advances in understanding and managing dry eye disease. Am J Ophthalmol. 2008;146(3):350–356. e351. doi:https://doi.org/10.1016/j.ajo.2008.05.016.
- Korb DR, Herman JP, Finnemore VM, Exford JM, Blackie CA. An evaluation of the efficacy of fluorescein, rose bengal, lissamine green, and a new dye mixture for ocular surface staining. Eye Contact Lens. 2008;34(1):61–64. doi:https://doi.org/10.1097/ICL.0b013e31811ead93.
- Yoon K-C, Im S-K, Kim H-G, You I-C. Usefulness of double vital staining with 1% fluorescein and 1% lissamine green in patients with dry eye syndrome. Cornea. 2011;30(9):972–976. doi:https://doi.org/10.1097/ICO.0b013e31820687dd.
- Chao W, Belmonte C, Benitez Del Castillo JM, et al. Report of the inaugural meeting of the TFOS i(2) = initiating innovation series: targeting the unmet need for dry eye treatment. Ocul Surf. 2016;14(2):264–316. doi:https://doi.org/10.1016/j.jtos.2015.11.003.
- Papas EB. Key factors in the subjective and objective assessment of conjunctival erythema. Invest Ophthalmol Vis Sci. 2000;41:687–691.
- Doane MG. Blinking and the mechanics of the lacrimal drainage system. Ophthalmology. 1981;88(8):844–851. doi:https://doi.org/10.1016/S0161-6420(81)34940-9.
- Nakamori K, Odawara M, Nakajima T, Mizutani T, Tsubota K. Blinking is controlled primarily by ocular surface conditions. Am J Ophthalmol. 1997;124(1):24–30. doi:https://doi.org/10.1016/S0002-9394(14)71639-3.
- Pult H, Riede-Pult BH, Murphy PJ. The relation between blinking and conjunctival folds and dry eye symptoms. Optometry Vision Sci. 2013;90(10):1034–1039. doi:https://doi.org/10.1097/OPX.0000000000000029.
- Arita R, Morishige N, Koh S, et al. Increased tear fluid production as a compensatory response to meibomian gland loss: a multicenter cross-sectional study. Ophthalmology. 2015;122(5):925–933. doi:https://doi.org/10.1016/j.ophtha.2014.12.018.
- Arita R, Itoh K, Maeda S, Maeda K, Tomidokoro A, Amano S. Efficacy of diagnostic criteria for the differential diagnosis between obstructive meibomian gland dysfunction and aqueous deficiency dry eye. Jpn J Ophthalmol. 2010;54(5):387–391. doi:https://doi.org/10.1007/s10384-010-0858-1.
- Serin D, Karsloglu S, Kyan A, Alagöz G. A simple approach to the repeatability of the Schirmer test without anesthesia: eyes open or closed? Cornea. 2007;26(8):903–906. doi:https://doi.org/10.1097/ICO.0b013e3180950083.
- Nichols KK, Mitchell GL, Zadnik K. The repeatability of clinical measurements of dry eye. Cornea. 2004;23(3):272–285. doi:https://doi.org/10.1097/00003226-200404000-00010.
- Yeh TN, Graham AD, Lin MC. Relationships among tear film stability, osmolarity, and dryness symptoms. Optom Vis Sci. 2015;92(9):e264. doi:https://doi.org/10.1097/OPX.0000000000000649.
- Caffery B, Chalmers RL, Marsden H, et al. Correlation of tear osmolarity and dry eye symptoms in convention attendees. Optometry Vision Sci. 2014;91(2):142–149. doi:https://doi.org/10.1097/OPX.0000000000000130.
- Amparo F, Jin Y, Hamrah P, Schaumberg DA, Dana R. What is the value of incorporating tear osmolarity measurement in assessing patient response to therapy in dry eye disease? Am J Ophthalmol. 2014;157(1):69–77. e62. doi:https://doi.org/10.1016/j.ajo.2013.07.019.
- Puderbach S, Stolze HH. Tear ferning and other lacrimal tests in normal persons of different ages. Int Ophthalmol. 1991;15(6):391–395. doi:https://doi.org/10.1007/BF00137950.
- Evans KS, North RV, Purslow C. Tear ferning in contact lens wearers. Ophthalmic Physiol Opt. 2009;29(2):199–204. doi:https://doi.org/10.1111/j.1475-1313.2008.00626.x.
- Corrales RM, Stern ME, De Paiva CS, Welch J, Li D-Q, Pflugfelder SC. Desiccating stress stimulates expression of matrix metalloproteinases by the corneal epithelium. Invest Ophthalmol Vis Sci. 2006;47(8):3293–3302. doi:https://doi.org/10.1167/iovs.05-1382.
- Sambursky R, Davitt WF, Latkany R, et al. Sensitivity and specificity of a point-of-care matrix metalloproteinase 9 immunoassay for diagnosing inflammation related to dry eye. JAMA Ophthalmol. 2013;131(1):24–28. doi:https://doi.org/10.1001/jamaophthalmol.2013.561.
- Sambursky R, Davitt WF III, Friedberg M, Tauber S. Prospective, multicenter, clinical evaluation of point-of-care matrix metalloproteinase-9 test for confirming dry eye disease. Cornea. 2014;33:812–818.
- Alhatem A, Cavalcanti B, Hamrah P. In vivo confocal microscopy in dry eye disease and related conditions. Paper presented at: Seminars in Ophthalmology; 2012.
- Craig JP, Singh I, Tomlinson A, Morgan PB, Efron N. The role of tear physiology in ocular surface temperature. Eye. 2000;14(4):635–641. doi:https://doi.org/10.1038/eye.2000.156.
- Tan J-H, Ng E, Acharya UR, Chee C. Infrared thermography on ocular surface temperature: a review. Infrared Physic Technol. 2009;52(4):97–108. doi:https://doi.org/10.1016/j.infrared.2009.05.002.
- Abreau K, Callan C, Kottaiyan R, et al. Temperatures of the ocular surface, lid, and periorbital regions of Sjögren’s, evaporative, and aqueous-deficient dry eyes relative to normals. Ocul Surf. 2016;14(1):64–73. doi:https://doi.org/10.1016/j.jtos.2015.09.001.
- Versura P, Giannaccare G, Fresina M, Campos EC. Subjective discomfort symptoms are related to low corneal temperature in patients with evaporative dry eye. Cornea. 2015;34:1079–1085.
- Canan H, Altan-Yaycioglu R, Ulas B, Sizmaz S, Coban-Karatas M. Interexaminer reproducibility of optical coherence tomography for measuring the tear film meniscus. Curr Eye Res. 2014;39(12):1145–1150. doi:https://doi.org/10.3109/02713683.2014.898311.
- Tomlinson A, Blades KJ, Pearce EI. What does the phenol red thread test actually measure? Optometry Vision Sci. 2001;78(3):142–146. doi:https://doi.org/10.1097/00006324-200103000-00005.
- Moore JE, Graham JE, Goodall EA, et al. Concordance between common dry eye diagnostic tests. British J Ophthalmol. 2009;93(1):66–72. doi:https://doi.org/10.1136/bjo.2007.131722.
- Masmali A, Alqahtani TA, Alharbi A, El-Hiti GA. Comparative study of repeatability of phenol red thread test versus Schirmer test in normal adults in Saudi Arabia. Eye Contact Lens. 2014;40(3):127–131. doi:https://doi.org/10.1097/ICL.0000000000000025.
- Shigeyasu C, Yamada M, Kawashima M, et al. Quality of life measures and health utility values among dry eye subgroups. Health Qual Life Outcomes. 2018;16(1):170. doi:https://doi.org/10.1186/s12955-018-0999-3.
- Tsubota K. Short tear film breakup time–type dry eye. Invest Ophthalmol Vis Sci. 2018;59(14):DES64–DES70. doi:https://doi.org/10.1167/iovs.17-23746.
- Özcura F, Aydin S, Helvaci MR. Ocular surface disease index for the diagnosis of dry eye syndrome. Ocul Immunol Inflamm. 2007;15(5):389–393. doi:https://doi.org/10.1080/09273940701486803.
- Vitale S, Goodman LA, Reed GF, Smith JA. Comparison of the NEI-VFQ and OSDI questionnaires in patients with Sjögren’s syndrome-related dry eye. Health Qual Life Outcomes. 2004;2(1):44. doi:https://doi.org/10.1186/1477-7525-2-44.
- McAlinden C, Gao R, Wang Q, et al. Rasch analysis of three dry eye questionnaires and correlates with objective clinical tests. Ocul Surf. 2017;15(2):202–210. doi:https://doi.org/10.1016/j.jtos.2017.01.005.
- Karakus S, Agrawal D, Hindman HB, Henrich C, Ramulu PY, Akpek EK. Effects of prolonged reading on dry eye. Ophthalmology. 2018;125(10):1500–1505. doi:https://doi.org/10.1016/j.ophtha.2018.03.039.
- Beck RW, Maguire MG, Bressler NM, Glassman AR, Lindblad AS, Ferris FL. Visual acuity as an outcome measure in clinical trials of retinal diseases. Ophthalmology. 2007;114(10):1804–1809. doi:https://doi.org/10.1016/j.ophtha.2007.06.047.
- Ferris FL III, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol. 1982;94(1):91–96. doi:https://doi.org/10.1016/0002-9394(82)90197-0.
- Group ETDRSR. Grading diabetic retinopathy from stereoscopic color fundus photographs—an extension of the modified Airlie House classification: ETDRS report number 10. Ophthalmology. 1991;98(5):786–806. doi:https://doi.org/10.1016/S0161-6420(13)38012-9.
- Ip MS, Zhang J, Ehrlich JS. The clinical importance of changes in diabetic retinopathy severity score. Ophthalmology. 2017;124(5):596–603. doi:https://doi.org/10.1016/j.ophtha.2017.01.003.
- Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701–713. doi:https://doi.org/10.1001/archopht.120.6.701.
- Leske MC, Heijl A, Hyman L, Bengtsson B, Group EMGT. Early manifest glaucoma trial: design and baseline data. Ophthalmology. 1999;106(11):2144–2153. doi:https://doi.org/10.1016/S0161-6420(99)90497-9.
- Bunya VY, Fernandez KB, Ying G-S, et al. A survey of ophthalmologists regarding practice patterns for dry eye and Sjogren’s syndrome. Eye Contact Lens. 2018;44(Suppl 2):S196. doi:https://doi.org/10.1097/ICL.0000000000000448.
- Koh S, Maeda N, Ikeda C, et al. The effect of ocular surface regularity on contrast sensitivity and straylight in dry eye. Invest Ophthalmol Vis Sci. 2017;58(5):2647–2651. doi:https://doi.org/10.1167/iovs.17-21894.
- Szczotka-Flynn LB, Maguire MG, Ying G-S, et al. Impact of dry eye on visual acuity and contrast sensitivity: dry eye assessment and management study. Optom Vis Sci. 2019;96(6):387. doi:https://doi.org/10.1097/OPX.0000000000001387.
- Mathews PM, Ramulu PY, Swenor BS, Utine CA, Rubin GS, Akpek EK. Functional impairment of reading in patients with dry eye. British J Ophthalmol. 2017;101(4):481–486. doi:https://doi.org/10.1136/bjophthalmol-2015-308237.
- Luo L, Li D-Q, Corrales RM, Pflugfelder SC. Hyperosmolar saline is a proinflammatory stress on the mouse ocular surface. Eye Contact Lens. 2005;31(5):186–193. doi:https://doi.org/10.1097/01.ICL.0000162759.79740.46.
- Luo L, Li D-Q, Doshi A, Farley W, Corrales RM, Pflugfelder SC. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Invest Ophthalmol Vis Sci. 2004;45(12):4293–4301. doi:https://doi.org/10.1167/iovs.03-1145.
- Kaufman HE. The practical detection of mmp-9 diagnoses ocular surface disease and may help prevent its complications. Cornea. 2013;32:211–216.
- Machado LM, Castro RS, Fontes BM. Staining patterns in dry eye syndrome: rose bengal versus lissamine green. Cornea. 2009;28:732–734.
- Feenstra RP, Tseng SC. Comparison of fluorescein and rose bengal staining. Ophthalmology. 1992;99:605–617.
- Coursey TG, Henriksson JT, Barbosa FL, de Paiva CS, Pflugfelder SC. Interferon-γ–induced unfolded protein response in conjunctival goblet cells as a cause of mucin deficiency in Sjögren syndrome. Am J Pathol. 2016;186:1547–1558.
- Massingale ML, Li X, Vallabhajosyula M, Chen D, Wei Y, Asbell PA. Analysis of inflammatory cytokines in the tears of dry eye patients. Cornea. 2009;28:1023–1027.
- Chambers W, Puglisi M E-mail Communication. In: Akpek E, ed 2020
- US Food and Drug Administration. Restasis approval package and labeling. United States Government. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-023_Restasis.cfm. Accessed September 1, 2020.
- Holland EJ, Whitley WO, Sall K, et al. Lifitegrast clinical efficacy for treatment of signs and symptoms of dry eye disease across three randomized controlled trials. Curr Med Res Opin. 2016;32(10):1759–1765.
- Semba CP, Torkildsen GL, Lonsdale JD, et al. A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye. Am J Ophthalmol. 2012;153(6):1050–1060. e1051.
- Sheppard JD, Torkildsen GL, Lonsdale JD, et al. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. Ophthalmology. 2014;121(2):475–483.
- Tauber J, Karpecki P, Latkany R, et al. Lifitegrast ophthalmic solution 5.0% versus placebo for treatment of dry eye disease: results of the randomized phase III OPUS-2 study. Ophthalmology. 2015;122(12):2423–2431.
- Goldberg DF, Malhotra RP, Schechter BA, Justice A, Weiss SL, Sheppard JD. A phase 3, randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye disease. Ophthalmology. 2019;126:1230–1237.
- Holland EJ, Nichols KK, Foulks GN, Gupta PK, Sall K, Coultas SL Efficacy and Safety of KPI-121 0.25% for Short Term Relief in Dry Eye (STRIDE). Paper presented at: 2020 ASCRS Annual Meeting2020. Virtual Meeting.
- Nichols KK, Evans DG, Karpecki PM. A comprehensive review of the clinical trials conducted for dry eye disease and the impact of the vehicle comparators in these trials. Curr Eye Res. 2020;46(5):609–614.